HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007)

Approximately 257 million people chronically infected with hepatitis B virus (HBV) worldwide are at risk of developing hepatocellular carcinoma (HCC). However, despite the availability of potent nucleoside/tide inhibitors, currently there are no curative therapies for chronic HBV infections. To iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalkeri, Raj, Peng, Junzhong, Huang, Chunsheng, Cai, Zhaohui, Ptak, Roger G., Suto, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582060/
https://www.ncbi.nlm.nih.gov/pubmed/33110426
http://dx.doi.org/10.1155/2020/8844061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582060/
https://www.ncbi.nlm.nih.gov/pubmed/33110426
http://dx.doi.org/10.1155/2020/8844061

Ejemplares similares